NCCN RECOMMENDS HEREDITARY CANCER TESTING FOR PATIENTS WITH PROSTATE CANCER THAT MEET ANY OF THE FOLLOWING¹,²:

- Metastatic Prostate Cancer (this includes distant metastasis and regional bed or nodes)
- High/Very High Risk Prostate Cancer
- Gleason Score 7 AND one of the following:
  - Ashkenazi Jewish Ancestry
  - 1 family member with metastatic prostate cancer
  - 1 family member with ovarian cancer
  - 1 family member with pancreatic cancer
  - 1 family member with breast cancer ≤ 50 years old
  - 2 family members on the same side of the family with breast or prostate cancer at any age

² NCCN® Clinical Practice Guidelines in Oncology - Prostate Cancer V.2.2019.
MEDICARE COVERS BRCA1/2 TESTING FOR PATIENTS WITH PROSTATE CANCER THAT MEET ANY OF THE FOLLOWING¹:

- Metastatic Prostate Cancer*
- Gleason Score 7+ AND one of the following:
  - Ashkenazi Jewish Ancestry
  - 1 family member with metastatic prostate cancer
  - 1 family member with ovarian cancer
  - 1 family member with pancreatic cancer
  - 1 family member with breast cancer ≤ 50 years old
  - 2 family members on the same side of the family with breast or prostate cancer (Gleason 7+ or metastatic) at any age

*Metastatic prostate cancer is biopsy proven and/or with radiographic evidence and includes distant metastasis and regional bed or nodes. It is not biochemical recurrence.²